Keros Therapeutics, Inc.
KROS
$11.58
$0.110.96%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 3.55M | 651.00K | 271.00K | 234.00K | 151.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.55M | 651.00K | 271.00K | 234.00K | 151.00K |
| Cost of Revenue | 18.29M | 44.32M | 29.23M | 21.25M | 14.08M |
| Gross Profit | -14.74M | -43.66M | -28.96M | -21.02M | -13.93M |
| SG&A Expenses | 40.75M | 39.19M | 38.52M | 37.36M | 34.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 214.38M | 204.69M | 188.93M | 179.79M | 170.09M |
| Operating Income | -210.83M | -204.03M | -188.66M | -179.56M | -169.94M |
| Income Before Tax | -187.05M | -181.57M | -168.05M | -160.30M | -152.99M |
| Income Tax Expenses | 300.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | -187.35 | -181.57 | -168.05 | -160.30 | -152.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -187.35M | -181.57M | -168.05M | -160.30M | -152.99M |
| EBIT | -210.83M | -204.03M | -188.66M | -179.56M | -169.94M |
| EBITDA | -209.60M | -202.89M | -187.62M | -178.63M | -169.13M |
| EPS Basic | -5.01 | -5.21 | -5.13 | -5.14 | -5.19 |
| Normalized Basic EPS | -3.13 | -3.25 | -3.20 | -3.21 | -3.25 |
| EPS Diluted | -6.42 | -6.62 | -6.46 | -6.47 | -6.52 |
| Normalized Diluted EPS | -3.13 | -3.25 | -3.20 | -3.21 | -3.25 |
| Average Basic Shares Outstanding | 149.72M | 139.51M | 131.58M | 125.08M | 117.77M |
| Average Diluted Shares Outstanding | 149.72M | 139.51M | 131.58M | 125.08M | 117.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
